Open Access Highly Accessed Case report

Case of a sigmoid colon cancer with metachronous metastases to the mesorectum and the abdominal wall

John Kalaitzis*, George Filippou, Adamantia Zizi-Sermpetzoglou, Athanasios Marinis, Andreas Hadjimarcou, Nikolaos Paschalidis and Spyros Rizos

Author Affiliations

1stDepartment of Surgery, General Hospital of Pireus Tzaneio, Athens, Greece

For all author emails, please log on.

World Journal of Surgical Oncology 2010, 8:17  doi:10.1186/1477-7819-8-17

Published: 21 March 2010

Abstract

Backround

Sigmoid colon cancer metachronous metastases commonly occur in the liver and lungs with sporadic reports also to the spleen, stomach, thyroid gland, abdominal wall and upper urinary tract. This is a rare case of metachronous metastases invading the mesorectum and the abdominal wall.

Case presentation

A 72-year-old female underwent sigmoidectomy for stage I (T2N0 M0) sigmoid colon cancer in May 2008. In June 2009, an abdominal computed tomography scan revealed a tumor 2 cm in size at the lower anterior mesorectum and a second mass 2 cm in size at the anterior abdominal wall midline. Total colonoscopy showed no mucosal lesion. The serum carcinoembryonic antigen level was normal. A biopsy of the mesorectum tumor showed similar histologic characteristics with the primary tumor. Since no other site of recurrence was identified, an abdominoperineal resection was attempted. During the operation and after the removal of the incision recurrence, sinus bradycardia and signs of myocardial ischemia were noticed. A loop transverse colostomy was immediately perfomed and the operation was terminated. Postoperative cardiologic examination revealed an acute myocardium infract. Chemo-radiation of the mesorectum tumor and re-evaluation for surgical excision was decided.

Conclusion

Metachronous metastasis of the mesorectum from sigmoid colon cancer is extremely rare. Although patterns of lymphatic spread from rectal cancer to sigmoid colon have recently been demonstrated, there is no evidence of metachronous mesorectum invasion from sigmoid colon cancer. This could be the issue for future trials.